中国现代医生2024，Vol.62Issue(23)：81-86,6.DOI:10.3969/j.issn.1673-9701.2024.23.018
外用皮炎方治疗表皮生长因子受体络氨酸激酶抑制剂相关性皮疹的临床疗效观察
Observation of the clinical efficacy of external application of piyan formula in treating EGFR-TKIs-related rash
摘要
Abstract
Objective To observe the clinical efficacy and safety of external application of Piyan Formula in treating epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKIs)-related rashes.Methods Sixty cases of EGFR-TKIs-related rash patients were randomly allocated into either a treatment group or a control group.The treatment group received external application of Piyan Formula to the rash area twice daily for 14 days.The control group received external application of fucidic acid cream to the rash area twice daily for 14 days.Changes in rash grading,itching grading,quality of life scores and adverse event were observed and recorded in both groups.At the same time,levels of hypersensitive C-reactive protein,interleukin(IL)-6,and IL-1β were measured before treatment and 24 hours after treatment.Results After treatment,the rash severity,itching severity,and quality of life scores were notably lower in the treatment group compared to the control group(P<0.05).The levels of hypersensitive C-reactive protein,IL-6,and IL-1β exhibited a significant decrease compared to their pre-treatment values.(P<0.05).Compared with the control group,the levels of hypersensitive C-reactive protein,IL-6,and IL-1β decreased in the treatment group,with statistically significant differences(P<0.05).No adverse events related to Piyan Formula or fucidic acid cream occurred during the treatment process.Conclusion External application of Piyan Formula in treating EGFR-TKIs-related rashes shows significant clinical efficacy,can effectively reduce the levels of inflammatory factors,and has high safety,thus warranting clinical promotion.关键词
外用/皮炎方/EGFR-TKIs相关性皮疹/临床疗效Key words
Topical/Piyan formula/EGFR-TKIs-related rash/Clinical efficacy/Inflammation分类
医药卫生引用本文复制引用
符磊,张慧,林天东,姜靖雯,李梅娇,王鹏,陈浪,黄剑秋,林少妃..外用皮炎方治疗表皮生长因子受体络氨酸激酶抑制剂相关性皮疹的临床疗效观察[J].中国现代医生,2024,62(23):81-86,6.基金项目
海南省重点研发项目(ZDYF2021SHFZ225) （ZDYF2021SHFZ225）
海南省卫生健康行业科研项目(21A200410) （21A200410）
国家中医药管理局全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]76号) （国中医药人教函[2022]76号）
国家中医药管理局第四届林天东传承工作室建设项目(国中医药办人教函[2022]245号) （国中医药办人教函[2022]245号）
